Product Description
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. (Sourced from: https://ashpublications.org/blood/article/123/1/94/32155/Crenolanib-is-a-potent-inhibitor-of-FLT3-with)
Mechanisms of Action: FLT3 Inhibitor,PGFRa Inhibitor,PGFRb Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arog
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Acute Myeloid Leukemia|Gastrointestinal Stromal Tumors
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2017-001600-29 | P3 |
Active, not recruiting |
Acute Myeloid Leukemia |
2024-05-30 |
|
| ARO-009 | P2 |
Completed |
Acute Myeloid Leukemia |
2022-05-01 |
|
| 2015-000287-34 | P3 |
Active, not recruiting |
Gastrointestinal Stromal Tumors |
2020-05-30 |
|
| CTR20200493 | P3 |
Not yet recruiting |
Acute Myeloid Leukemia |
None |